Tekla Capital Management’s Moderna MRNA Stock Holding History

Tekla Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$41.8M	Buy	343,695 +21,478	+7%	+$2.87M	1.63%	17
2023 Q1	$49.5M	Buy	322,217 +57,290	+22%	+$9.45M	1.88%	17
2022 Q4	$47.6M	Sell	264,927 -49,997	-16%	-$8.17M	1.8%	18
2022 Q3	$37.2M	Sell	314,924 -13,600	-4%	-$2.06M	1.52%	22
2022 Q2	$46.9M	Hold	328,524	–	–	1.84%	17
2022 Q1	$56.6M	Sell	328,524 -218,100	-40%	-$36.7M	1.99%	17
2021 Q4	$139M	Buy	546,624 +87,168	+19%	+$25.5M	4.47%	2
2021 Q3	$177M	Sell	459,456 -6,321	-1%	-$2.33M	5.69%	1
2021 Q2	$109M	Sell	465,777 -6,525	-1%	-$1.17M	3.56%	4
2021 Q1	$61.8M	Buy	472,302 +224,110	+90%	+$32.5M	2.13%	12
2020 Q4	$25.9M	Sell	248,192 -212,167	-46%	-$21.5M	0.91%	32
2020 Q3	$32.6M	Sell	460,359 -32,147	-7%	-$2.24M	1.22%	19
2020 Q2	$31.6M	Buy	492,506 +238,360	+94%	+$13.1M	1.2%	21
2020 Q1	$7.61M	Buy	+254,146	New	+$5.85M	0.34%	59

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tekla Capital Management's MRNA Position: Q2 2023 in Review

Tekla Capital Management increased its Moderna (MRNA) stake by 6.7% in Q2 2023, buying an estimated $2.87M and bringing the position to 343,695 shares worth $41.8M. The position accounts for 1.63% of the portfolio, ranked #17.

Tekla Capital Management first reported a position in MRNA in Q1 2020 and has held it in 14 quarters since. The position peaked at $177M in Q3 2021. 966 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

Tekla Capital Management held 343,695 shares of Moderna worth $41.8M as of Q2 2023.
Tekla Capital Management bought 21,478 Moderna shares in Q2 2023, an estimated $2.87M.
Moderna made up 1.63% of Tekla Capital Management's portfolio in Q2 2023, its #17 holding.
Tekla Capital Management first reported a position in Moderna in Q1 2020 and has held it in 14 quarters since.
Tekla Capital Management's Moderna position peaked at $177M in Q3 2021.
966 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.